Association of CYP2D6*10 (C. 100 c>t) genotype with z-end concentration in patients with breast cancer receiving tamoxifen therapy in indonesian population

Yenny, Sonar S. Panigoro, Denni J. Purwanto, Adi Hidayat, Melva Louisa, Rizka Andalusia, Rianto Setiabudy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Tamoxifen (TAM) is a frequently used hormonal prodrug for patients with breast cancer that needs to be activated by cytochrome P450 2D6 (CYP2D6) into Zusammen-endoxifen (Z-END). Objective: The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer. Methods: A cross-sectional study was performed in 125 ambulatory patients with breast cancer consuming TAM at 20 mg/day for at least 4 months. The frequency distribution of CYP2D6*10 (c.100C>T) genotypes (C/C: Wild type; C/T: Heterozygous mutant; T/T: Homozygous mutant) was detected using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), the results of which were subsequently confirmed by sequencing. The genotypes were categorized into plasma Z- END concentrations of <5.9 ng/mL and ≥5.9 ng/mL, which were measured using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Results: Percentages of C/C, CT, and T/T genotypes were 22.4%, 29.6%, and 48.8%, respectively. Median (25-75%) Z-END concentrations in C/C, C/T, and T/T genotypes were 9.58 (0.7-6.0), 9.86 (0.7-26.6), and 3.76 (0.9-26.6) ng/mL, respectively. Statistical analysis showed a significant difference in median Z-END concentration between patients with T/T genotype and those with C/C or C/T genotypes (p<0.001). There was a significant association between CYP2D6*10 (c.100C>T) genotypes and attainment of plasma steady-state Z-END MTC (p<0.001). Conclusion: There was a significant association between CYP2D6*10 (c.100C>T) and attainment of plasma steady-state Z-END MTC in Indonesian breast cancer patients receiving TAM at a dose of 20 mg/day.

Original languageEnglish
Pages (from-to)1198-1206
Number of pages9
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume19
Issue number8
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • Breast cancer
  • Indonesian population
  • Steady state concentration
  • Tamoxifen
  • Z-endoxifen

Fingerprint Dive into the research topics of 'Association of CYP2D6*10 (C. 100 c>t) genotype with z-end concentration in patients with breast cancer receiving tamoxifen therapy in indonesian population'. Together they form a unique fingerprint.

  • Cite this